 The objectives were: 1 To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohns disease who participated in NCT00055523; 2 To delineate the safety of adalimumab when administered to participants with Crohns disease up to 56 weeks. 